Literature DB >> 28283864

Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.

Trilokesh D Kidambi1, Christina Pedley2, Amie Blanco2, Emily K Bergsland2,3, Jonathan P Terdiman4,5,6.   

Abstract

Lower gastrointestinal (GI) neuroendocrine neoplasms (NENs) of the colon and rectum are uncommon and not traditionally associated with hereditary GI cancer syndromes. However, with widespread implementation of colorectal cancer screening programs, lower GI NENs are being identified with increasing frequency. We report the first case series of six patients with lower GI NENs who were diagnosed with hereditary GI cancer syndromes by germline testing. Two patients presented with poorly differentiated rectal neuroendocrine carcinoma (NECs) with colonic polyposis and were found to have Familial Adenomatous Polyposis and MYH-Associated Polyposis, respectively. Three patients with colorectal NENs (one well differentiated neuroendocrine tumor, NET, and two NECs), all of which displayed abnormal immunohistochemistry for mismatch repair proteins, were diagnosed with Lynch syndrome. One patient with a goblet cell carcinoid was diagnosed with CHEK2 mutations. All patients met genetic testing guidelines and the diagnosis was made utilizing next generation sequencing gene panel tests. Lower GI NETs should therefore be considered a potential hereditary GI cancer syndrome-associated malignancy in patients who otherwise meet criteria for genetic evaluation.

Entities:  

Keywords:  Hereditary colon cancer; Lynch syndrome; Neuroendocrine tumor; Polyposis

Mesh:

Substances:

Year:  2017        PMID: 28283864     DOI: 10.1007/s10689-017-9979-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  24 in total

1.  An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer.

Authors:  Catherine Miquel; Jean-Christophe Sabourin; Dominique Elias; Sophie Grandjouan; Jérôme Viguier; Michel Ducreux; Pierre Duvillard; Françoise Praz
Journal:  Hum Pathol       Date:  2004-12       Impact factor: 3.466

Review 2.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

3.  A molecularly confirmed neuroendocrine tumor resulting from Lynch Syndrome.

Authors:  Steven Sorscher; Bikramajit Saroya
Journal:  J Gastrointest Oncol       Date:  2013-03

4.  Coexisting carcinoid tumors in familial adenomatous polyposis-associated upper intestinal adenomas.

Authors:  L V July; K A Northcott; E M Yoshida; D M Carr; D A Owen
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 6.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Günter Klöppel; Guido Rindi; Martin Anlauf; Aurel Perren; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

7.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer.

Authors:  Francis M Giardiello; John I Allen; Jennifer E Axilbund; C Richard Boland; Carol A Burke; Randall W Burt; James M Church; Jason A Dominitz; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David A Lieberman; Douglas J Robertson; Sapna Syngal; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2014-07-22       Impact factor: 10.864

8.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

Authors:  Rachel Pearlman; Wendy L Frankel; Benjamin Swanson; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Sandya Liyanarachchi; Matthew Kalady; Brandie Heald; Carla Greenwood; Ian Paquette; Marla Prues; David J Draper; Carolyn Lindeman; J Philip Kuebler; Kelly Reynolds; Joanna M Brell; Amy A Shaper; Sameer Mahesh; Nicole Buie; Kisa Weeman; Kristin Shine; Mitchell Haut; Joan Edwards; Shyamal Bastola; Karen Wickham; Karamjit S Khanduja; Rosemary Zacks; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Brian Allen; Albert de la Chapelle; Heather Hampel
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

9.  The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.

Authors:  Caitlin B Mauer; Sara M Pirzadeh-Miller; Linda D Robinson; David M Euhus
Journal:  Genet Med       Date:  2013-10-10       Impact factor: 8.822

10.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.

Authors:  Holly LaDuca; A J Stuenkel; Jill S Dolinsky; Steven Keiles; Stephany Tandy; Tina Pesaran; Elaine Chen; Chia-Ling Gau; Erika Palmaer; Kamelia Shoaepour; Divya Shah; Virginia Speare; Stephanie Gandomi; Elizabeth Chao
Journal:  Genet Med       Date:  2014-04-24       Impact factor: 8.822

View more
  2 in total

Review 1.  When should genetic testing be performed in patients with neuroendocrine tumours?

Authors:  Triona O'Shea; Maralyn Druce
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 2.  Upper Gastrointestinal Cancer Surveillance in Lynch Syndrome.

Authors:  Shria Kumar; Natalie Farha; Carol A Burke; Bryson W Katona
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.